Project Grant R21DA061122
Award Date
9/15/24
Completion Date
8/31/26
Dollars Obligated
$476K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Indiana, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $399,536 to Chemregen Inc.'s Human Biomolecular Research Institute in San Diego, CA. The funding supports research to design, synthesize, and test non-opioid drug candidates as potential treatments for opioid use disorder and fentanyl toxicity. Key objectives include characterizing the effects of opioids on human induced pluripotent stem...
The National Institute on Drug Abuse (NIDA) awarded a $1,539,426 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to Serodopa Therapeutics Inc. to develop a novel intranasal formulation of a naloxone derivative for the reversal of opioid-induced respiratory depression caused by high-potency opioids such as fentanyl. The project aims to complete formulation development, preclinical toxicology and safety testing required to prepare an Investigational New Drug (IND)...
This federal Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $671,732 to The Washington University to conduct research on the mechanisms underlying fentanyl-induced cardiorespiratory depression. The goal is to evaluate the use of peripherally-acting mu opioid receptor (MOR) antagonists to prevent and reverse fentanyl overdoses without the aversive withdrawal effects seen with naloxone. The research also aims...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a research study focused on understanding the impact of the opioid fentanyl on individuals with HIV. The total funding amount is $587,188, with the award period running from July 15, 2025 to March 31, 2030. The key products and services to be delivered under this grant include: A multi-omics approach and complementary in vivo and ex vivo studies to...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research on the impact of fentanyl consumption on noradrenergic plasticity in the basolateral amygdala. The $184,706 award to the University of North Carolina at Chapel Hill will fund a 5-year study to investigate how patterns of fentanyl consumption and withdrawal alter brainstem noradrenergic neurons and disrupt norepinephrine signaling in the...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $267,310 to the University of Miami to assess the functional role of calcitonin gene-related peptide (CGRP) expressing neurons within the parabrachial nucleus (CGRPPBN) in opioid reinforcement and to determine the associated gene expression and epigenetic changes. The goal is to explore non-opioid targets to treat opioid use disorder, a...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $139,927 to the University of Washington to assess the impact of chronic, voluntary fentanyl intake on gene expression and neural activity patterns in the brain. The key objectives are to: 1) conduct single-cell RNA sequencing in the nucleus accumbens to analyze changes in gene expression after chronic fentanyl use and withdrawal, and 2)...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to investigate the role of cholinergic interneurons in the ventral tegmental area on opioid-related behaviors. The $373,181 grant, awarded on July 15, 2024 with a completion date of June 30, 2027, aims to determine whether mu-opioid receptors on cholinergic interneurons contribute to opioid reward, consumption, and withdrawal, and how...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $772,800 to the University of Florida to conduct research on pharmacologically targeting novel modulators of opioid signaling. The overarching goal is to dissociate the behavioral effects associated with opioid receptor activation to curb the development of dependence and tolerance. The research will involve using high-throughput screening...
This Project Grant from the National Institutes of Health National Institute on Drug Abuse, under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $889,713 to The Ohio State University from April 2021 through March 2023. The funding supports research to develop dual-cavity baskets assembled into nanoparticles as nano-antidotes for overdose with fentanyl and its derivatives. Specifically, the awardee will functionalize dual-cavity baskets with biocompatible groups to trap...